Phase 3 N=238 Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
COPD · Eosinophilia
Primary: Time From Randomisation to Next Hospital Readmission or Death (All Cause) — 25.7; 24.4 Weeks — p=0.811
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=41 A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection Recurrence
Primary: Number of Participants With RBX2660-related Treatment-emergent Adverse Events (TEAEs) After RBX2660 Treatment Delivered by Colonoscopy Through 8 Weeks, or Treatment…
Phase 3 N=1,407 A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Obesity
Primary: Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight — -19.5; -3.8 Percentage (%) change in body weight — p=<0.0001
Phase 3 N=17 Neuroimaging Study of Dexmedetomidine-Induced Analgesia
Analgesia · Anesthesia
Primary: CSF Flow Measured in Hz — -15 Hz
Phase 3 N=559 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Type 2 Diabetes
Primary: Change From Baseline in HbA1c — -0.15; -1.26; -1.59; -1.45 percentage of HbA1c — p=<.001
Phase 3 N=116 Does Montelukast Decrease Post Adenotonsillectomy Pain in Children
Pain
Primary: Postoperative Physician Contacts — 20; 24 participants
Phase 3 N=112 Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
Otomycosis
Primary: Number of Participants With Clinical Cure — 19; 18 Participants
Phase 3 N=243 A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.
COVID-19
Primary: Number of Participants With Improvement in at Least Two Categories in WHO 8-point Ordinal Clinical Scale at Day 28 or Discharge — 106; 104 Participants — p=0.1513
Phase 3 N=905 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
COVID-19 · SARS-CoV-2 Infection
Primary: Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs] — 34294.3; 36142.6; 33233.4; 91945.8 Elisa…
Phase 3 N=33 A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs)…
Phase 3 N=98 Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
Leber Hereditary Optic Neuropathy
Primary: Change From Baseline of the Best Corrected Visual Acuity (BCVA) Reported With Log of the Minimal Angle of Resolution (LogMAR) at 1.5 Years Post-treatment, in the Second…
Phase 3 N=129 A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
Primary: Number of Participants With Sputum Culture Conversion in Mycobacteria Growth Indicator Tube (MGIT) at Week 24 — 3; 16 Participants — p==0.002
Phase 3 N=396 Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea
Diarrhea · Cholera
Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941
Phase 3 N=278 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Geographic Atrophy · Age-Related Macular Degeneration
Primary: Number of Participants With Adverse Events (AEs) — 50; 49; 129 Participants
Phase 3 N=108 Loss of RESponse to Ustekinumab Treated by Dose Escalation
Crohn Disease
Primary: Proportion of Patients With Steroid Free Clinical Remission and Fecal Calprotectin<250µg/g at Week 48 — 8; 10 Participants — p=0.5